PRINT OUT

News Release 2016

December 19, 2016 Nippon Shinyaku enters into a license agreement with Pharmacosmos on an intravenous iron therapy, Monofer® (iron isomaltoside 1000) <HTML>
December 05, 2016 Nippon Shinyaku Co. Ltd. Announces Data Presentations at the 58th American Society of Hematology Annual Meeting <HTML>
November 21, 2016 Launch of Uptravi® Tablet for the Treatment of Pulmonary Arterial Hypertension <HTML>
November 10, 2016 Presentation Material for IR Meeting <PDF>
November 09, 2016 FDA Grants Fast Track Designation to NS-065/NCNP-01 for the Treatment of Duchenne Muscular Dystrophy <HTML>
November 08, 2016 Outline of Consolidated Financial Results for the Second Quarter Ended September 30, 2016 <PDF>
November 08, 2016 Revision of Performance Projection, Dividend of Surplus (Interim Dividend) and Revision of Year-end Dividend Forecast <PDF>
October 18, 2016 Revision of Performance Projection <PDF>
September 28, 2016 Nippon Shinyaku receives manufacturing and marketing authorization for Uptravi for Treatment of Pulmonary Arterial Hypertension. <HTML>
September 08, 2016 Notice of Publishment of Annual Report 2016 <HTML>
August 08, 2016 Outline of Consolidated Financial Results for the First Quarter Ended June 30, 2016 <PDF>
August 08, 2016 Presentation Material for IR Meeting <PDF>
June 21, 2016 Selexipag, Originally Discovered and Synthesized by Nippon Shinyaku, Granted Orphan Drug Designation for the Indication of Chronic Thromboembolic Pulmonary Hypertension. <HTML>
June 02, 2016 Notice Of The 153rd Annual General Meeting Of Shareholders <HTML>
May 17, 2016 Actelion is granted marketing authorization for Uptravi (selexipag) in pulmonary arterial hypertension by the European Commission <HTML>
May 16, 2016 Presentation Material for IR Meeting <PDF>
May 12, 2016 Discontinuance (Abolition) of Policies concerning Large-Scale Purchases of the Company's Shares (Takeover Defense Measures) <HTML>
May 12, 2016 Outline of Consolidated Financial Results for the Year Ended March 31, 2016 <PDF>
March 30, 2016 An IND for Phase 2 Clinical Study of NS-065, a Treatment for Duchenne Muscular Dystrophy, Submitted in the US <HTML>
March 24, 2016 Nippon Shinyaku Co., Ltd. announces final completion of API* manufacturing building <HTML>
February 08, 2016 Outline of Consolidated Financial Results for the Third Quarter Ended December 31, 2015 <PDF>
February 08, 2016 Presentation Material for IR Meeting <PDF>
February 02, 2016 Phase 1/2 Clinical Study of NS-065, a Treatment for Duchenne Muscular Dystrophy, Initiated <HTML>
February 01, 2016 Our licensee YooYoung Pharmaceutical launches a treatment for allergic rhinitis in South Korea, originally developed by Nippon Shinyaku <HTML>
January 07, 2016 Nippon Shinyaku Submits NDA to MHLW for Selexipag for Treatment of Pulmonary Arterial Hypertension. <HTML>
get_adobe_reader
page-top